<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[vytorin Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/vytorin.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to vytorin]]></description>
	<s:counts start="0" returned="15" found="15" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Schering-Plough's Hassan Made Stock Gains as Price Tumbled and Layoffs Grew]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000230/schering-ploughs-hassan-made-stock-gains-as-price-tumbled-and-layoffs-grew/]]></link>
		<description><![CDATA[About 1,000 sales reps are being let go from Schering-Plough this week. That's on top of 60 animal health reps also being fired. Roughly 5,500 employees in general are being axed in Schering-Plough's cost-cutting drive.    If you're one of those people, comfort yourself with the fact that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 19 Sep 2008 08:36:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/fred+hassan.html"><![CDATA[Fred Hassan]]></category>
		<category domain="http://resources.bnet.com/topic/sgp.html"><![CDATA[SGP]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough Now in the Feds' Crosshairs]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2699&messageID=13002&start=0]]></link>
		<description><![CDATA[Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Thu, 10 Jul 2008 17:19:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/trial+result.html"><![CDATA[trial result]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2684&messageID=12779&start=0]]></link>
		<description><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Mon, 07 Jul 2008 14:41:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[How Pharma Stacks the Deck with Medical Journals]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=2548&messageID=12068&start=0]]></link>
		<description><![CDATA[How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness:  The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Wed, 18 Jun 2008 21:31:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/enhance+trial.html"><![CDATA[ENHANCE Trial]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/trial+result.html"><![CDATA[trial result]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zocor.html"><![CDATA[Zocor]]></category>
	</item>
	<item>
		<title><![CDATA[Schering-Plough Now in the Feds' Crosshairs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100065/schering-plough-now-in-the-feds-crosshairs/]]></link>
		<description><![CDATA[The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious:  Investigation and Inquiries.Ã‚Â Ã‚Â Through the date     of filing this     10-Q,     Schering-Plough, the joint venture     and/or its  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 07 May 2008 16:44:51 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/attorney.html"><![CDATA[Attorney]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Is Merck Hanging Schering Out to Dry on Vytorin?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100043/is-merck-hanging-schering-out-to-dry-on-vytorin/]]></link>
		<description><![CDATA[A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin.    Vytorin, of course, is a combination...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 23 Apr 2008 14:25:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cholesterol.html"><![CDATA[Cholesterol]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck, Schering Unable to Stop Digging in Vytorin Mess]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100021/merck-schering-unable-to-stop-digging-in-vytorin-mess/]]></link>
		<description><![CDATA[As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough  sat on for a year or two after it showed that Vytorin was apparently no better than a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 14 Apr 2008 16:26:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/house+committee.html"><![CDATA[House Committee]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Vytorin Update: Big Pharma Strikes Back]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100017/vytorin-update-big-pharma-strikes-back/]]></link>
		<description><![CDATA[The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash.    Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 03 Apr 2008 09:36:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Vytorin Update: Big Pharma Strikes Back]]></title>
		<link><![CDATA[http://blogs.bnet.com/intercom/?p=1734]]></link>
		<description><![CDATA[The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash.    Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 03 Apr 2008 09:23:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/trial.html"><![CDATA[Trial]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Marketing Trumps Science in Vytorin Scandal]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/100018/marketing-trumps-science-in-vytorin-scandal/]]></link>
		<description><![CDATA[In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 09:37:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/zetia.html"><![CDATA[Zetia]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Marketing Trumps Science in Vytorin Scandal]]></title>
		<link><![CDATA[http://blogs.bnet.com/intercom/?p=1721]]></link>
		<description><![CDATA[In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Apr 2008 09:11:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/online+communications.html"><![CDATA[Online Communications]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/e-mail.html"><![CDATA[E-mail]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/schering.html"><![CDATA[Schering]]></category>
		<category domain="http://resources.bnet.com/topic/zetia.html"><![CDATA[Zetia]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN®  Superior to Lipitor  in Reducing LDL "Bad" Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_21/ai_n27092078]]></link>
		<description><![CDATA[Greater LDL Cholesterol Reduction with VYTORIN Compared to Lipitor Resulted in Greater LDL Cholesterol Goal Attainment]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 21 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/lipitor.html"><![CDATA[Lipitor]]></category>
		<category domain="http://resources.bnet.com/topic/mayo+clinic.html"><![CDATA[Mayo Clinic]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Approves New Label for VYTORIN®]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Oct_5/ai_n27046208]]></link>
		<description><![CDATA[New Label Includes Data Demonstrating VYTORIN Lowered LDL "Bad" Cholesterol more than Crestor at all Doses Compared]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 05 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Merck and Schering-Plough&#39;s statin combo hits pharmacies]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qa5351/is_200409/ai_n21356348]]></link>
		<description><![CDATA[THE STATIN category got a new addition last month following FDA approval of Merck and Schering-Plough's Vytorin (ezetimibe/simvastatin), which combines Merck's Zocor and Zetia from Schering-Plough. Vytorin was expected in pharmacies by Labor Day. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 01 Sep 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">MRK,SGP</category>
	</item>
	<item>
		<title><![CDATA[Generic competition threatens AstraZeneca.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200408/ai_n26014075]]></link>
		<description><![CDATA[The US launch this month of cholesterol-lowering drug Vytorin could  mean thinner pickings for AstraZeneca's product, Crestor.    The US launch this month of cholesterol-lowering drug Vytorin could  mean thinner pickings for AstraZeneca's product, Crestor.  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 20 Aug 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/vytorin.html"><![CDATA[Vytorin]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
</channel>
</rss>
